IVIG - BMC HealthNet Plan

Barre syndrome: report of the Quality Standards Subcommittee of the American
Academy of Neurology. Neurology. 2003;61:736-740.
71. Van Doorn P, Kuitwaard K, Walgaard C, et al. IVIG treatment and prognosis in
Guillain-Barre Syndrome. J Clin Immunol. 2010;30 Suppl1:s74-78.
72. Howard JF. Myasthenia gravis a manual for the health care provider. Myasthenia
Gravis Foundation of America, Inc.
73. Jahnke L, Applebaum S, Sherman LA, et al. An evaluation of intravenous
immunoglobulin in the treatment of human immunodeficiency virus-associated
thrombocytopenia. Transfusion. 1994;34:759-764.
74. Scaradavou A, Cunningham-Rundles S, Ho JL, et al. Superior effect of intravenous
anti-D compared with IV gammaglobulin in the treatment of HIV-thrombocytopenia:
results of a small, randomized prospective comparison. Am. J. Hematol. 2007;82:335-
341.
75. WinRho® SDF [package insert]. Westlake Village, CA: Baxter Healthcare
Corporation (manufactured by Cangene Corporation, Winnipeg, Canada); April 2006.
76. Comi G, Roveri L, Swan A, et al; Inflammatory Neuropathy Cause and Treatment
Group. A randomised controlled trial of intravenous immunoglobulin in IgM
paraprotein associated demyelinating neuropathy. J Neurol. 2002;249:1370-1377.
77. Joint Task Force of the EFNS and the PNS. European Federation of Neurological
Societies/Peripheral Nerve Society Guideline on management of paraproteinemic
demyelinating neuropathies. Report of a Joint Task Force of the European Federation
of Neurological Societies and the Peripheral Nerve Society—first revision. J Peripher
Nerv Syst. 2010;15(3):185-95.
78. Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome.
Cochrane Database Syst Rev. 2003;(2):CD003279.
79. Sederholm BH. Treatment of chronic immune-mediated neuropathies: chronic
inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy,
and the Lewis-Sumner Syndrome. Semin Neurol. 2010;30(4):443-456.
80. Hughes RA; Joint Task Force of the EFNS and the PNS. European Federation of
Neurological Societies/Peripheral Nerve Society Guideline on management of
multifocal motor neuropathy. Report of a joint task force of the European Federation
of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst.
2006;11:1-8.
81. The NCCN Prevention Multiply Myeloma Clinical Practice Guidelines in Oncology
(Version 1.2011). © 2010 National Comprehensive Cancer Network, Inc. Available
at: http://www.nccn.org. Accessed December 28, 2010.
82. Drugs and lactation database of the National Library of Medicine’s TOXNET system
(Globulin, Immune). Last revised: December 7, 2010. Available at:
http://toxnet.nlm.nih.gov. Accessed on January 20, 2011.
83. Hellwig K, Beste C, Schimrigk S and Chan A. Immunomodulation and postpartum
relapses in patients with multiple sclerosis. Ther Adv Neurol Disord. 2009;2(1):7-11.
This guideline provides information on BMC HealthNet Plan claims adjudication processing guidelines. The use of this
guideline is not a guarantee of payment and will not determine how a specific claim(s) will be paid. Reimbursement is
based on member benefits and eligibility, medical necessity review, where applicable, coordination of benefits, adherence
to Plan policies, clinical coding criteria, and the BMC HealthNet Plan agreement with the rendering or dispensing provider.
Reimbursement policies may be amended at BMC HealthNet Plan’s discretion. BMC HealthNet Plan will always use the
most recent CPT and HCPCS coding guidelines.
BMC HealthNet Plan – IVIG
38 of 45